NASDAQ:RXRX Recursion Pharmaceuticals (RXRX) Stock Forecast, Price & News $8.93 +0.27 (+3.12%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$8.43▼$9.0450-Day Range$4.56▼$9.2552-Week Range$4.54▼$14.18Volume1.75 million shsAverage Volume2.97 million shsMarket Capitalization$1.72 billionP/E RatioN/ADividend YieldN/APrice Target$12.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Recursion Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside38.9% Upside$12.40 Price TargetShort InterestBearish17.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.05Based on 6 Articles This WeekInsider TradingSelling Shares$1.26 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.41) to ($1.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector644th out of 1,009 stocksBiological Products, Except Diagnostic Industry99th out of 167 stocks 3.2 Analyst's Opinion Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.40, Recursion Pharmaceuticals has a forecasted upside of 38.9% from its current price of $8.93.Amount of Analyst CoverageRecursion Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.27% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 2.15%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRecursion Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecursion Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RXRX. Previous Next 3.4 News and Social Media Coverage News SentimentRecursion Pharmaceuticals has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Recursion Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest14 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,258,288.00 in company stock.Percentage Held by Insiders22.25% of the stock of Recursion Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.62% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.41) to ($1.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recursion Pharmaceuticals is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recursion Pharmaceuticals is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecursion Pharmaceuticals has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Recursion Pharmaceuticals (NASDAQ:RXRX) StockRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Read More Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RXRX Stock News HeadlinesMay 29, 2023 | finance.yahoo.comRecursion Pharmaceuticals Is Going Big on AI. Here's Why It Could Be Worth BuyingMay 26, 2023 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.8% May 30, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 25, 2023 | finance.yahoo.comAltitude Lab Relocates to Gateway’s BioHive HubMay 24, 2023 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 6.8%May 23, 2023 | msn.comRecursion extends gains in AI-driven rallyMay 22, 2023 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Coverage Initiated by Analysts at Morgan StanleyMay 19, 2023 | americanbankingnews.comBlake Borgeson Sells 8,885 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) StockMay 30, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 16, 2023 | finance.yahoo.comRecursion Appoints David Mauro, M.D., Ph.D., as Chief Medical OfficerMay 13, 2023 | americanbankingnews.comKeyCorp Comments on Recursion Pharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:RXRX)May 11, 2023 | americanbankingnews.comBrokers Set Expectations for Recursion Pharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:RXRX)May 10, 2023 | marketwatch.com8-K: RECURSION PHARMACEUTICALS, INC.May 10, 2023 | americanbankingnews.comEquities Analysts Set Expectations for Recursion Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:RXRX)May 10, 2023 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPSMay 9, 2023 | markets.businessinsider.comNeedham Keeps Their Buy Rating on Recursion Pharmaceuticals (RXRX)May 9, 2023 | markets.businessinsider.comExpert Ratings for Recursion PharmaceuticalsMay 9, 2023 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analysts Just Trimmed Their Revenue Forecasts By 11%May 9, 2023 | seekingalpha.comRecursion Pharmaceuticals GAAP EPS of -$0.34, revenue of $12.13MMay 8, 2023 | markets.businessinsider.comBerenberg Bank Sticks to Its Buy Rating for Recursion Pharmaceuticals (RXRX)May 8, 2023 | finance.yahoo.comRecursion Provides Business Updates and Reports First Quarter 2023 Financial ResultsMay 8, 2023 | finance.yahoo.comRecursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue EstimatesMay 8, 2023 | americanbankingnews.comInsider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells $155,773.83 in StockApril 29, 2023 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 52-Week Low at $4.84April 21, 2023 | americanbankingnews.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson Sells 8,885 SharesApril 19, 2023 | msn.comNeedham Reiterates Recursion Pharmaceuticals, Inc. (RXRX) Buy RecommendationApril 15, 2023 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 6.5%See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RXRX Company Calendar Last Earnings5/08/2023Today5/29/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXRX CUSIPN/A CIK1601830 Webwww.recursion.com Phone385-269-0203Fax801-821-2872Employees400Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.40 High Stock Price Forecast$20.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+38.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-239,480,000.00 Net Margins-533.45% Pretax Margin-533.45% Return on Equity-57.15% Return on Assets-38.10% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual Sales$39.84 million Price / Sales43.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.54 per share Price / Book3.52Miscellaneous Outstanding Shares192,360,000Free Float149,559,000Market Cap$1.72 billion OptionableNot Optionable Beta-0.43 Key ExecutivesDr. Christopher C. Gibson Ph.D. (Age 40)Co-Founder, CEO & Director Comp: $673.59kMs. Tina Marriott Larson (Age 48)COO & Pres Comp: $595.95kDr. Blake C. Borgeson Ph.D. (Age 41)Co-Founder & Director Comp: $30kDr. Michael Secora Ph.D. (Age 40)Chief Financial Officer Comp: $510.34kDr. Shafique Virani M.D. (Age 52)Interim Chief Medical Officer & Chief Bus. Officer Comp: $688.17kKevin LeggatVP of Fin. & AccountingMr. Benjamin Mabey M.S. (Age 40)Chief Technology Officer Mr. Jared AllenbachSr. Director of Investor RelationsMs. Louisa Daniels J.D. (Age 65)M.B.A., Chief Legal Officer & Gen. Counsel Mr. Ryan KellyChief Communications OfficerMore ExecutivesKey CompetitorsVericelNASDAQ:VCELBioCryst PharmaceuticalsNASDAQ:BCRXKymera TherapeuticsNASDAQ:KYMRSpringWorks TherapeuticsNASDAQ:SWTXIovance BiotherapeuticsNASDAQ:IOVAView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 3,809 shares on 5/26/2023Ownership: 0.015%JPMorgan Chase & Co.Bought 136,178 shares on 5/18/2023Ownership: 0.161%New York State Common Retirement FundSold 23,882 shares on 5/18/2023Ownership: 0.037%Titleist Asset Management LLCBought 35,750 shares on 5/18/2023Ownership: 0.019%Blake BorgesonSold 8,885 sharesTotal: $45,224.65 ($5.09/share)View All Insider TransactionsView All Institutional Transactions RXRX Stock - Frequently Asked Questions Should I buy or sell Recursion Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXRX, but not buy additional shares or sell existing shares. View RXRX analyst ratings or view top-rated stocks. What is Recursion Pharmaceuticals' stock price forecast for 2023? 5 Wall Street analysts have issued 12 month target prices for Recursion Pharmaceuticals' shares. Their RXRX share price forecasts range from $8.00 to $20.00. On average, they anticipate the company's stock price to reach $12.40 in the next twelve months. This suggests a possible upside of 38.9% from the stock's current price. View analysts price targets for RXRX or view top-rated stocks among Wall Street analysts. How have RXRX shares performed in 2023? Recursion Pharmaceuticals' stock was trading at $7.71 on January 1st, 2023. Since then, RXRX stock has increased by 15.8% and is now trading at $8.93. View the best growth stocks for 2023 here. When is Recursion Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our RXRX earnings forecast. How were Recursion Pharmaceuticals' earnings last quarter? Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.01. The company had revenue of $12.13 million for the quarter, compared to analysts' expectations of $15.93 million. Recursion Pharmaceuticals had a negative trailing twelve-month return on equity of 57.15% and a negative net margin of 533.45%. What ETFs hold Recursion Pharmaceuticals' stock? ETFs with the largest weight of Recursion Pharmaceuticals (NASDAQ:RXRX) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), ARK Genomic Revolution ETF (ARKG), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), WisdomTree Artificial Intelligence and Innovation Fund (WTAI), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). When did Recursion Pharmaceuticals IPO? (RXRX) raised $306 million in an initial public offering on Friday, April 16th 2021. The company issued 18,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO. What is Recursion Pharmaceuticals' stock symbol? Recursion Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXRX." Who are Recursion Pharmaceuticals' major shareholders? Recursion Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (13.14%), BlackRock Inc. (5.56%), State Street Corp (3.33%), FMR LLC (2.49%), ARK Investment Management LLC (1.87%) and Platinum Investment Management Ltd. (1.45%). Insiders that own company stock include Blake Borgeson, Christopher Gibson, Dean Y Li, Mubadala Investment Co Pjsc, Shafique Virani and Tina Marriott Larson. View institutional ownership trends. How do I buy shares of Recursion Pharmaceuticals? Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Recursion Pharmaceuticals' stock price today? One share of RXRX stock can currently be purchased for approximately $8.93. How much money does Recursion Pharmaceuticals make? Recursion Pharmaceuticals (NASDAQ:RXRX) has a market capitalization of $1.72 billion and generates $39.84 million in revenue each year. The company earns $-239,480,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. How many employees does Recursion Pharmaceuticals have? The company employs 400 workers across the globe. How can I contact Recursion Pharmaceuticals? Recursion Pharmaceuticals' mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. The official website for the company is www.recursion.com. The company can be reached via phone at 385-269-0203, via email at investorrelations@recursion.com, or via fax at 801-821-2872. This page (NASDAQ:RXRX) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.